Roth MKM Initiates Coverage On Chemomab Therapeutics With Buy Rating, Announces Price Target of $7
Roth MKM Initiates Coverage On Chemomab Therapeutics With Buy Rating, Announces Price Target of $7
Roth MKM以买入评级开始对Chemomab Therapeutics进行报道,宣布目标股价为7美元
Roth MKM analyst Dylan Dupuis initiates coverage on Chemomab Therapeutics (NASDAQ:CMMB) with a Buy rating and announces Price Target of $7.
Roth MKM分析师迪伦·杜普伊斯以买入评级开始对Chemomab Therapeutics(纳斯达克股票代码:CMMB)进行报道,并宣布目标股价为7美元。
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。